| Name | AZD5582 acetate (1258392-53-8 free base) |
| Description | AZD5582 acetate is an inhibitor of IAPs, which binds to the BIR3 domains cIAP1, cIAP2, and XIAP with IC50s of 15, 21, and 15 nM, respectively. AZD5582 induces apoptosis. |
| In vitro | AZD5582 (20 nM; 48 hours) inhibited cell viability by cooperation with IFNγ or viral double-stranded RNA (dsRNA) in H1975 NSCLC cells[2]. AZD5582 (20 nM; 48 hours) involves in apoptosis due to induction of cell death and active caspase-3/ -8 activities by AZD5582 and IFNγ co-treatment in HCC827 NSCLC cells[2]. AZD5582 (20 nM; 17 or 25 hours) down-regulates cIAP-1, activates RIPK1( upstream regulator of caspase-8), and triggers the activation of extrinsic (caspase-8) and intrinsic (caspase-9) apoptosis pathways, causing the cleavage of caspase-3 and caspase-7[2]. |
| In vivo | AZD5582 (intravenous injection; 0.1-3.0 mg/kg; once a week; 2 weeks) causes degradation of cIAP1 and caspase 3 cleavage in tumor cells, and after a two-week treatment, the tumors largely resolved. When the mice are given a medium dose (0.5 mg/kg) of AZD5582, cIAP1 degrades after administration, but it takes a while time to reach apoptosis-inducing effect[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 55 mg/ml (51.15 mM)
|
| Keywords | 1258392-53-8 free base | AZD 5582 Acetate | 1258392-53-8 | AZD-5582 Acetate | AZD5582 Acetate | AZD-5582 acetate (1258392-53-8 free base) | AZD5582 acetate (1258392538 free base) | AZD5582 acetate (1258392 53 8 free base) |
| Inhibitors Related | LCL161 | MX69 | Se-Methylselenocysteine | HM90822 | BV6 | 1-[2,4-Dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-2-propen-1-one | AZD5582 TFA | N-Deshydroxyethyl Dasatinib | Xevinapant | Acacetin | ASTX660 | Birinapant |
United States
